Cantor Fitzgerald Predicts Tourmaline Bio FY2025 Earnings

Key Points

• Analysts from Cantor Fitzgerald have revised their FY2025 earnings estimate for Tourmaline Bio to ($3.85) per share, down from a previous estimate of ($3.15), indicating a potential decline in performance.
• The company reported Q2 earnings of ($0.90) per share, better than the consensus estimate of ($0.94), suggesting it is currently outperforming some expectations.
• Tourmaline Bio has received a majority of "buy" ratings from analysts, with a consensus target price of $50.14 per share reflecting positive market sentiment.

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Investment analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for shares of Tourmaline Bio in a report released on Thursday, August 14th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings per share of ($3.85) for the year, down from their previous estimate of ($3.15). The consensus estimate for Tourmaline Bio's current full-year earnings is ($3.02) per share. Cantor Fitzgerald also issued estimates for Tourmaline Bio's FY2026 earnings at ($3.76) EPS.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.90) EPS for the quarter, beating analysts' consensus estimates of ($0.94) by $0.04.

Other equities analysts have also issued research reports about the stock. Chardan Capital reiterated a "buy" rating and issued a $70.00 price target on shares of Tourmaline Bio in a report on Thursday, August 14th. HC Wainwright reiterated a "buy" rating and issued a $50.00 price target on shares of Tourmaline Bio in a report on Monday, May 5th. Finally, Guggenheim reiterated a "buy" rating and issued a $55.00 price target on shares of Tourmaline Bio in a report on Thursday, August 14th. Seven research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $50.14.

Tourmaline Bio Stock Up 1.9%

NASDAQ TRML traded up $0.4350 during trading hours on Monday, hitting $22.8950. 43,098 shares of the stock were exchanged, compared to its average volume of 287,262. The company has a market cap of $588.06 million, a price-to-earnings ratio of -6.67 and a beta of 2.04. Tourmaline Bio has a 12-month low of $11.56 and a 12-month high of $29.79. The stock has a 50-day moving average of $19.25 and a 200 day moving average of $16.69.

Institutional Trading of Tourmaline Bio

Large investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC boosted its holdings in shares of Tourmaline Bio by 297.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,646 shares of the company's stock worth $33,000 after buying an additional 1,232 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Tourmaline Bio by 34.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,103 shares of the company's stock valued at $34,000 after buying an additional 535 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Tourmaline Bio by 35.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,214 shares of the company's stock valued at $51,000 after acquiring an additional 846 shares in the last quarter. Brooklyn Investment Group boosted its stake in shares of Tourmaline Bio by 148.9% in the 1st quarter. Brooklyn Investment Group now owns 3,923 shares of the company's stock valued at $60,000 after purchasing an additional 2,347 shares during the last quarter. Finally, Virtus ETF Advisers LLC bought a new position in Tourmaline Bio during the 4th quarter worth approximately $64,000. 91.89% of the stock is owned by institutional investors.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.